London stock exchange listed OptiBiotix Health plc, a life sciences business developing compounds to tackle obesity, highcholesterol and diabetes, has announced the filing of two new patents covering its cholesterol reducing product. This increases the number of patents from nine to eleven.
Company said on Tuesday in a press release that it believes that filing these patents adds a further layer of protection to its intellectual property portfolio, creates valuable assets, and increases the number of product opportunities.
Stephen O’Hara, CEO of OptiBiotix, commented:
“We are pleased to announce the filing of these patents which add a further level of protection and value to our cholesterol reducing product. We believe these patents will further enhance the value proposition and negotiating position with commercial partners and make a significant contribution to building a successful and sustainable business for shareholders.”